Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

Orange, 2006, Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, J. Allergy Clin. Immunol., 117, S525, 10.1016/j.jaci.2006.01.015

Wood, 2007, Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review, Clin. Exp. Immunol., 149, 410, 10.1111/j.1365-2249.2007.03432.x

Bonilla, 2005, Practice parameter for the diagnosis and management of primary immunodeficiency, Ann. Allergy Asthma Immunol., 94, S1, 10.1016/S1081-1206(10)61142-8

Roifman, 1987, High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease, Lancet, 1, 1075, 10.1016/S0140-6736(87)90494-6

Gelfand, 1988, Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high- versus low-dose therapy, Monogr. Allergy, 23, 177

Roifman, 1988, Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia, Pediatr. Infect. Dis. J., 7, S92, 10.1097/00006454-198805001-00017

Liese, 1992, High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia, Am. J. Dis. Child., 146, 335

Eijkhout, 2001, The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial, Ann. Intern. Med., 135, 165, 10.7326/0003-4819-135-3-200108070-00008

Berger, 2008, Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency, Immunol. Allergy Clin. N. Am., 28, 413, 10.1016/j.iac.2008.01.008

Yong, 2010, Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology, Clin. Immunol., 135, 255, 10.1016/j.clim.2009.10.003

Roifman, 2008, Management of primary antibody deficiency with replacement therapy: summary of guidelines, Immunol. Allergy Clin. N. Am., 28, 875, 10.1016/j.iac.2008.07.003

Bonagura, 2008, Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection, J. Allergy Clin. Immunol., 122, 210, 10.1016/j.jaci.2008.04.044

Kainulainen, 1999, Pulmonary abnormalities in patients with primary hypogammaglobulinemia, J. Allergy Clin. Immunol., 104, 1031, 10.1016/S0091-6749(99)70085-0

Quartier, 1999, Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients, J. Pediatr., 134, 589, 10.1016/S0022-3476(99)70246-5

Busse, 2007, Pulmonary complications of common variable immunodeficiency, Ann. Allergy Asthma Immunol., 98, 1, 10.1016/S1081-1206(10)60853-8

Winkelstein, 2006, X-linked agammaglobulinemia: report on a United States registry of 201 patients, Medicine (Baltimore), 85, 193, 10.1097/01.md.0000229482.27398.ad

Winkelstein, 2003, The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients, Medicine (Baltimore), 82, 373, 10.1097/01.md.0000100046.06009.b0

Hanson, 2008, Hypomorphic nuclear factor-κB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity, J. Allergy Clin. Immunol., 122, 1169, 10.1016/j.jaci.2008.08.018

Sullivan, 1994, A multiinstitutional survey of the Wiskott–Aldrich syndrome, J. Pediatr., 125, 876, 10.1016/S0022-3476(05)82002-5

Plebani, 2002, Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study, Clin. Immunol., 104, 221, 10.1006/clim.2002.5241

Busse, 2002, Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency, J. Allergy Clin. Immunol., 109, 1001, 10.1067/mai.2002.124999

Aghamohammadi, 2004, Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia, FEMS Immunol. Med. Microbiol., 40, 113, 10.1016/S0928-8244(03)00304-3

Pourpak, 2006, Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency, J. Microbiol. Immunol. Infect., 39, 114

Church, 2006, Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency, J. Clin. Immunol., 26, 388, 10.1007/s10875-006-9025-3

Stein, 2009, Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies, J. Clin. Immunol., 29, 137, 10.1007/s10875-008-9231-2

Berger, 2004, Subcutaneous immunoglobulin replacement in primary immunodeficiencies, Clin. Immunol., 112, 1, 10.1016/j.clim.2004.02.002

Greenland, 1987, Quantitative methods in the review of epidemiologic literature, Epidemiol. Rev., 9, 1, 10.1093/oxfordjournals.epirev.a036298

Bayrakci, 2005, The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID), Turk. J. Pediatr., 47, 239

Ammann, 1982, Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial, Clin. Immunol. Immunopathol., 22, 60, 10.1016/0090-1229(82)90022-8

Schiff, 1984, Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage, Clin. Immunol. Immunopathol., 31, 13, 10.1016/0090-1229(84)90185-5

Chapel, 2000, The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy, J. Clin. Immunol., 20, 94, 10.1023/A:1006678312925

Berger, 2004, Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases, J. Clin. Immunol., 24, 389, 10.1023/B:JOCI.0000029108.18995.61

Ochs, 2004, Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases, J. Clin. Immunol., 24, 309, 10.1023/B:JOCI.0000025453.23817.3f

Berger, 2007, A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma, J. Clin. Immunol., 27, 628, 10.1007/s10875-007-9107-x

Berger, 2007, Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases, J. Clin. Immunol., 27, 503, 10.1007/s10875-007-9096-9

Krasovec, 2007, Efficacy and tolerability of an Argentine intravenous immunoglobulin in pediatric patients with primary immunodeficiency diseases, J. Clin. Immunol., 27, 227, 10.1007/s10875-006-9055-x

Chapel, 2009, Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions, Br. J. Haematol., 145, 709, 10.1111/j.1365-2141.2009.07669.x

M.E. Rose, D.M. Lang, Evaluating and managing hypogammaglobulinemia, Cleve. Clin. J. Med. 73 (2006) 133-137, 140, 143-134.

Shehata, 2010, The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline, Transfus. Med. Rev., 24, S28, 10.1016/j.tmrv.2009.09.011

Notarangelo, 2007, Genetic causes of bronchiectasis: primary immune deficiencies and the lung, Respiration, 74, 264, 10.1159/000101784

Rich, 2008, Serial lung function tests in primary immune deficiency, Clin. Exp. Immunol., 151, 110, 10.1111/j.1365-2249.2007.03550.x

Roifman, 2003, Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial, Int. Immunopharmacol., 3, 1325, 10.1016/S1567-5769(03)00134-6